{
    "clinical_study": {
        "@rank": "137955", 
        "acronym": "TRANSNEP", 
        "arm_group": [
            {
                "arm_group_label": "rTMS of the motor cortex (Magventure)", 
                "arm_group_type": "Experimental", 
                "description": "experimental : rTMS of the motor cortex : repetitive magnetic stimulation targeting the motor cortex assisted by neuronavigation"
            }, 
            {
                "arm_group_label": "rTMS placebo (magventure)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "sham stimulation of the motor or prefrontal cortex with the placebo face of the device"
            }, 
            {
                "arm_group_label": "rTMS prefrontal cortex (magventure)", 
                "arm_group_type": "Experimental", 
                "description": "Experimental : repetitive transcranial stimulation targeting the prefrontal cortex as indicated by neuronavigation"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to evaluate the long term efficacy over 25 weeks of repeated sessions of\n      magnetic transcranial stimulation of the motor cortex or prefrontal cortex on average pain\n      intensity, quality of life, sleep, neuropathic symptoms, return to work, in patients with\n      peripheral neuropathic pain.\n\n      The medical device of study: transcranial magnetic stimulator (TMS)."
        }, 
        "brief_title": "Analgesic Effects of rTMS in Peripheral Neuropathic Pain", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Neuropathic Pain", 
        "condition_browse": {
            "mesh_term": "Neuralgia"
        }, 
        "detailed_description": {
            "textblock": "The present multicenter parallel session randomized placebo controlled study (4 French\n      centers) aims to evaluate the long term efficacy over 25 weeks of repeated sessions of\n      magnetic transcranial stimulation of the motor cortex or prefrontal cortex on average pain\n      intensity (primary outcome) and several secondary outcome measures (e.g. quality of life,\n      sleep, neuropathic symptoms, return to work), in patients with peripheral neuropathic pain.\n\n      The patients will be randomized to receive one of 3 treatment arms : rTMS of the motor\n      cortex, rTMS of the prefrontal cortex, or placebo (sham stimulation) of the motor or\n      prefrontal cortex. The study will be double blind, eg the patient and the investigator will\n      not know the nature of treatment. the stimulation protocol will consist of an induction\n      phasse of 5 daily sessions then a maintenance phase of several sessions : 3 sessions a week\n      apart, 3 sessions a fortnight apart, and 3 sessions 3 weeks apart."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Peripheral neuropathic pain (unilateral or bilateral) probable or defined according\n             to the criteria proposed in 2008 (Treede et al 2008),\n\n          2. Diagnostic DN4 questionnaire score greater than or equal to 4/10 (Bouhassira et al\n             2005),\n\n          3. chronic pain, the average intensity is greater than or equal to 40/100\n\n          4. Daily or almost daily pain (at least 4 days out of 7)\n\n          5. This pain is present for more than 6 months\n\n          6. Patients over 18 and under 75 years old\n\n          7. Patients  who signed informed consent,\n\n          8. Patients whose pain medication is stable for 15 days before inclusion, and will not\n             need to be changed during the study period,\n\n          9. Patients who can be monitored during the study period (30 weeks)\n\n         10. Patients insured by a health insurance plan or entitled.\n\n        Exclusion Criteria:\n\n          1. Previous treatment using  rTMS,\n\n          2. Work Accident or dispute\n\n          3. rTMS Cons-indications  (ECT treatment during the previous month, epilepsy and / or a\n             history of epilepsy; history of head trauma, neurosurgical lesion, intracranial\n             hypertension, metal clip, pacemaker, pregnant or lactating women)\n\n          4. Abuse of drugs or psychoactive substances (DSM IV)\n\n          5. Central neuropathic pain,\n\n          6. Neuropathic pain within the framework of a progressive disease (HIV, cancer,\n             non-stabilized system disease)\n\n          7. Neuropathic pain very limited extent, of neuroma type\n\n          8. Current major depression or psychosis according to DSM IV criteria,\n\n          9. Intermittent pain,\n\n         10. Pain for less than six months,\n\n         11. Presence of another pain more severe than the one justifying the inclusion\n\n         12. Lack of proper filling of self-assessment of pain from baseline and randomization (at\n             least 4 weekly pain scores 7 days) notebooks\n\n         13. Lack of stability of pain scores on two successive evaluations, defined as a change\n             of more than 30% between the two assessments of the average pain on the short\n             questionnaire about pain between the first two visits inclusion\n\n         14. Subject unable to understand informed consent, under guardianship,\n\n         15. Subject who refuses to stop or can not stop prohibited treatment during the study,\n\n         16. Patients participating in another research protocol involving a drug within 30 days\n             before enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "230", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02010281", 
            "org_study_id": "P120126", 
            "secondary_id": "AOM 120141"
        }, 
        "intervention": {
            "arm_group_label": [
                "rTMS of the motor cortex (Magventure)", 
                "rTMS placebo (magventure)", 
                "rTMS prefrontal cortex (magventure)"
            ], 
            "description": "description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation", 
            "intervention_name": "rTMS of prefrontal or motor cortex", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "rTMS", 
            "peripheral neuropathic pain", 
            "randomized controlled trial"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "contact": {
                "email": "nadine.attal@apr.aphp.fr", 
                "last_name": "NADINE ATTAL, MD", 
                "phone": "+33(1)49095931"
            }, 
            "facility": {
                "address": {
                    "city": "Boulogne Billancourt", 
                    "country": "France", 
                    "state": "Hauts-de-Seine", 
                    "zip": "92106"
                }, 
                "name": "Pain evaluation and treatement center, CHU Ambroise Par\u00e9"
            }, 
            "investigator": {
                "last_name": "NADINE ATTAL, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "Long-term Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) of the Motor or Prefrontal Cortex in Peripheral Neuropathic Pain: a Multicenter Randomized Placebo Controlled Trial", 
        "overall_contact": {
            "email": "nadine.attal@apr.aphp.fr", 
            "last_name": "NADINE ATTAL, MD", 
            "phone": "+33 (1) 49095931"
        }, 
        "overall_official": {
            "affiliation": "Pain evaluation and treatment center, CHU A Par\u00e9, 92104 Boulogne Billancourt, France", 
            "last_name": "NADINE ATTAL, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in average pain intensity from baseline to week 25, average pain intensity corresponds to average pain over the last 24 hours on the Brief Pain Inventory", 
            "measure": "Change in average pain intensity from baseline to week 25", 
            "safety_issue": "No", 
            "time_frame": "each visit for up to 25 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02010281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "change in minimal pain over the last 24 hours on the Brief Pain inventory", 
                "measure": "change in minimal pain intensity over the last 24 hours from baseline to week 25", 
                "safety_issue": "No", 
                "time_frame": "each visit for up 25 weeks"
            }, 
            {
                "description": "quality of life on the Eurogol questionnaire", 
                "measure": "quality of life", 
                "safety_issue": "No", 
                "time_frame": "each visit up to 25 weeks"
            }, 
            {
                "description": "Proportion of responders (patients whose pain is improved by at least 30% and 50% compared to their pain before treatment", 
                "measure": "Proportion of responders to rTMS", 
                "safety_issue": "No", 
                "time_frame": "at the end of treatment (25 weeks)"
            }, 
            {
                "description": "Evaluation of predictors of response (nature of neuropathic symptoms, severity of anxiety or depressive symptoms, presence or absence of mechanical allodynia, or dramatization importance of catastrophism related to pain)", 
                "measure": "Predictors of the response", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "Collection of side effects at each session and between sessions of rTMS", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "each follow up visit for up to 25 weeks"
            }, 
            {
                "description": "Determine the onset of the analgesic effect based on patient pain diaries for up to 1 month", 
                "measure": "Onset of the analgesic effect of rTMS", 
                "safety_issue": "No", 
                "time_frame": "one mont afer the beginning of rTMS"
            }, 
            {
                "description": "Return to work on a specific questionnaire at the end of the study", 
                "measure": "Return to work", 
                "safety_issue": "No", 
                "time_frame": "25 weeks"
            }, 
            {
                "description": "Maximal pain over the past 24 hours on the Brief Pain Inventory", 
                "measure": "Maximal pain", 
                "safety_issue": "Yes", 
                "time_frame": "each visit up to 25 weeks"
            }, 
            {
                "description": "Pain right now immediately after each rtMS session and between sessions for up to 25 weeks", 
                "measure": "Pain right now", 
                "safety_issue": "No", 
                "time_frame": "each visit up to 25 weeks"
            }, 
            {
                "description": "sleep quality and quantity on MOS sleep", 
                "measure": "Sleep", 
                "safety_issue": "No", 
                "time_frame": "each visit up to 25 weeks"
            }, 
            {
                "description": "Neuropathic symptoms on the Neuropathic Pain Symptom Inventory", 
                "measure": "Neuropathic symptoms", 
                "safety_issue": "No", 
                "time_frame": "each visit up to 25 weeks"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}